Table 2 Primary and secondary efficacy outcomes by day 28
Efficacy outcomes | Tocilizumab group (N = 56) | Usual care group (N = 58) | p value |
|---|---|---|---|
Primary outcome | |||
 Mortality (patients: N, %) | 9 (16.1%) | 19 (32.8%) | 0.03 |
Secondary outcomes | |||
 Time to discharge (days)/patients discharged alive by day 28 (N, %) | 11.0 (95% CI: 9.0 to 16.0)/39 (69.6%) | 14.0 (95% CI:10.0–24.0)/36 (62.1%) | 0.21 |
 ΔPaO2/FiO2 ( Day 5–Day1) | 42.0 (23.0–84.7) | 15.8 (− 19.4–50.3) | 0.03 |
 ΔWHO scale (Day 10–Day 1) | − 0.5 ± 2.1 | 0.6 ± 2.6 | 0.005 |